Financials
| Final Results | May. 08, 2025 |
| FY24 trading update | Feb. 27, 2025 |
| Half-year Report | Sep. 04, 2024 |
| Final Results | Jun. 28, 2024 |
| Half-year Report | Sep. 07, 2023 |
| Half-year Report | Sep. 07, 2023 |
| Final Results | May. 26, 2023 |
Proxies
| Result of AGM | Jun. 09, 2025 |
| Result of AGM | Jul. 24, 2024 |
| Result of AGM | Jun. 28, 2023 |
| Result of AGM | Jun. 29, 2022 |
| Result of AGM | Jul. 13, 2021 |
| Result of AGM | Jul. 13, 2020 |
| Result of AGM | Jul. 25, 2019 |
Ownership Update
| Holding(s) in Company | Sep. 11, 2025 |
| Holding(s) in Company | May. 06, 2025 |
| Holding(s) in Company | Dec. 11, 2024 |
| Repricing of Options and Grant of Options | Jul. 29, 2024 |
| PDMR Dealing | Jul. 18, 2024 |
| Holding(s) in Company | Jun. 19, 2024 |
| Holding(s) in Company | Jun. 19, 2024 |
Announcements
| Notice of Results | Sep. 16, 2025 |
| Submission of new Phase III study protocol to FDA | Aug. 12, 2025 |
| Block Listing Six Monthly Return | Jul. 24, 2025 |
| Promotion & sales representative agreement | Jun. 24, 2025 |
| FDA expands XENOVIEW indication | Jun. 02, 2025 |
| Dr. Bastiaan Driehuys awarded by ATS | May. 21, 2025 |
| Xenon MRI featured prominently at ATS 2025 | May. 15, 2025 |